Jean-François Pujol

Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France.

Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France.

Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France.

Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France.